Bristol-Myers Squibb

YTD

ALL

Trade Bristol-Myers Squibb 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About BMY

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies.

CEO

Christopher S. Boerner

CEOChristopher S. Boerner

Employees

34,100

Employees34,100

Headquarters

Princeton, New Jersey

HeadquartersPrinceton, New Jersey

Founded

1933

Founded1933

Employees

34,100

Employees34,100

BMY Key Statistics

Market cap

96.41B

Market cap96.41B

Price-Earnings ratio

18.04

Price-Earnings ratio18.04

Dividend yield

5.08%

Dividend yield5.08%

Average volume

12.34M

Average volume12.34M

High today

$48.23

High today$48.23

Low today

$47.26

Low today$47.26

Open price

$48.08

Open price$48.08

Volume

10.72M

Volume10.72M

52 Week high

$63.33

52 Week high$63.33

52 Week low

$41.61

52 Week low$41.61

BMY News

TipRanks 8h

Bristol-Myers Squibb’s New Alzheimer’s Study: A Potential Game Changer?

Bristol-Myers Squibb Company ((BMY)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium...

TipRanks 1d

Bristol-Myers Squibb’s Promising Study on Advanced Solid Tumors

Bristol-Myers Squibb Company ((BMY)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium...

TipRanks 1d

Bristol-Myers Squibb and Pfizer Stocks Jump on Eliquis Drug Discount

Bristol-Myers Squibb (BMY) and Pfizer (PFE) have revealed plans to sell their Eliquis blood thinner directly to patients at a discounted price, reports The Wall...

Analyst ratings

71%

of 28 ratings

Buy

25%

Hold

71.4%

Sell

3.6%

More BMY News

Benzinga 4d

Is Bristol-Myers Squibb Still An Undervalued Biopharma Play?

Bristol-Myers Squibb & Co. BMY is gearing up to announce its second-quarter 2025 earnings on July 31, with expectations for adjusted earnings of $1.585 per shar...

People also own

Based on the portfolios of people who own BMY. This list is generated using Robinhood data, and it’s not a recommendation.